• 42% of attacks reached complete headache relief following early treatment vs 28% following late treatment at 1 hour after administration. No significant difference in pain severity at 1 hour (P=.24)2†
• 62% of attacks reached complete headache relief following early treatment vs 55% following late treatment at 2 hours after administration. No significant difference in pain severity at 2 hours (P=.57)2†
• Mean time from first experience of pain to injection was 1 hour and 36 minutes for early treatment and 7 hours and 16 minutes for late treatment2†
Most Common Adverse Reactions: In controlled clinical trials with sumatriptan injection, the most common adverse reactions were injection site reactions, tingling, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, feeling of tightness, numbness, feeling strange, tight feeling in head, flushing, tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort, dizziness/vertigo, drowsiness/ sedation and headache.
*Two well-controlled clinical trials (N=1104) with patients experiencing moderate or severe pain and 1 or more migraine symptoms, evaluating efficacy of SQ sumatriptan vs placebo. The primary endpoints in the clinical trials were pain relief at 1 and 2 hours. Relief is defined as a reduction in pain from severe or moderately severe to mild or no headache.
†Open, prospective, crossover study (N=20) with patients who had used sumatriptan regularly without any contraindications for at least 6 months in acute migraine, with or without aura according to the International Headache Society criteria, during the previous 12 months. Two attacks (n=40) were treated with 6 mg subcutaneous sumatriptan as early as possible after the onset of migraine headache and 2 attacks (n=40) were treated as late as the patients could bear with at least a 48-hour sumatriptan-free period between the attacks.